Cargando…
非小细胞肺癌新辅助免疫治疗生物标志物研究进展
Surgery is the standard treatment for resectable non-small cell lung cancer (NSCLC). Neoadjuvant and adjuvant therapy have been widely used for preventing recurrence and metastasis. Immune checkpoint inhibitors (ICIs) have brought long-term survival benefits in advanced NSCLC and showed higher downs...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913284/ https://www.ncbi.nlm.nih.gov/pubmed/35224967 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.04 |